Cells were seeded in T-25 flasks at ∼2.5 × 10
5 cells per flasks in 4 ml of cell-specific media and exposed to compounds at 0.5
μM for 24 h, 48 h or 72 h. Protein was prepared from treated cells using
RIPA lysis buffer (Sigma) and quantified using the Bradford protein assay with
Bradford reagent (Sigma). Equal amounts of protein were loaded in all wells (15
μg). Proteins were separated by electrophoresis through a 4–12%
NuPAGE Bis-Tris gel (Invitrogen) and subsequently transferred to
Hybond-P membrane (GE Healthcare, Buckinghamshire, UK).
Detection was carried out using anti-human cyclin B1 (ref. H433; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA),
phospho-Bcl2 (ref. 2827S; Cell Signaling Technology, Boston, MA, USA),
caspase-3 (ref. 9665; Cell Signaling),
GAPDH (ref. 2118; Cell Signaling) and p53 (ref. ab28-100; Abcam, Cambridge, UK) primary antibodies. Secondary alkaline phosphatase-conjugated anti-rabbit IgG (ref. 7054; Cell Signaling) or anti-mouse IgG (ref 7056; Cell Signaling) antibodies were used for detection in conjunction with a chemifluorescent substrate (ECF substrate, ref. RPN5785; GE Healthcare). Bands were visualised and quantified using a
Storm imaging system (GE Healthcare).
Stengel C., Newman S.P., Day J.M., Chander S.K., Jourdan F.L., Leese M.P., Ferrandis E., Regis-Lydi S., Potter B.V., Reed M.J., Purohit A, & Foster P.A. (2014). In vivo and in vitro properties of STX2484: a novel non-steroidal anti-cancer compound active in taxane-resistant breast cancer. British Journal of Cancer, 111(2), 300-308.